GSO ASTM F2901:2021
Gulf Standard
Current Edition
·
Approved on
01 July 2021
·
Standard Guide for Selecting Tests to Evaluate Potential Neurotoxicity of Medical Devices
GSO ASTM F2901:2021 Files
English
3 Pages
Current Edition
Reference Language
GSO ASTM F2901:2021 Scope
1.1 Medical devices may cause adverse effects on the
structure and/or function of the nervous system. In this guide,
these adverse effects are defined as neurotoxicity. This guide
provides background information and recommendations on
methods for neurotoxicity testing. This guide should be used
with Practice F748, and may be helpful where neurotoxicity
testing is needed to evaluate medical devices that contact
nervous system tissue or cerebral spinal fluid (CSF).
1.2 This standard does not purport to address all of the
safety concerns, if any, associated with its use. It is the
responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.
Best Sellers From Health Sector
GSO 2017:2023
Gulf Standard
Personal Care and Baby Wet Wipes
BH GSO 2017:2023
GSO 2017:2023
Bahraini Standard
Personal Care and Baby Wet Wipes
BH GSO 2241:2023
GSO 2241:2023
Bahraini Standard
Cosmetic Products - Body Cleaners
GSO 2241:2023
Gulf Standard
Cosmetic Products - Body Cleaners
Recently Published from Health Sector
GSO ISO 17069:2024
ISO 17069:2020
Gulf Standard
Accessible design — Consideration and assistive products for accessible meeting
GSO ISO 11608-6:2024
ISO 11608-6:2022
Gulf Standard
Needle-based injection systems for medical use — Requirements and test methods — Part 6: On-body delivery systems
GSO ISO 16256:2024
ISO 16256:2021
Gulf Standard
Clinical laboratory testing and in vitro diagnostic test systems — Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against yeast fungi involved in infectious diseases
GSO ISO 14708-3:2024
ISO 14708-3:2017
Gulf Standard
Implants for surgery — Active implantable medical devices — Part 3: Implantable neurostimulators